What is Datavant?
Founded in 2017 and headquartered in San Francisco, Datavant operates at the intersection of software engineering and medical research. The company provides a robust platform designed to link and share healthcare data across disparate systems, thereby accelerating clinical research and enhancing patient care outcomes. By prioritizing data safety and interoperability, Datavant addresses the systemic inefficiencies that have historically hindered the utility of health information. Its enterprise-grade solutions are essential for organizations looking to leverage longitudinal patient data while maintaining rigorous privacy standards, positioning the firm as a foundational layer in the modern healthcare data stack.
How much funding has Datavant raised?
Datavant has raised a total of $121M across 3 funding rounds:
Series A
$40.5M
Other Financing Round
$40.5M
Series B
$40M
Series A (2018): $40.5M with participation from Roivant Sciences
Other Financing Round (2018): $40.5M led by Roivant Sciences
Series B (2020): $40M supported by Flex Capital, Roivant Sciences Ltd., Cigna Ventures, Transformation Capital Group Ltd, and Johnson & Johnson Innovation – JJDC, Inc.
Key Investors in Datavant
Roivant Sciences
A tech-enabled healthcare organization that focuses on the development of innovative drug candidates and the deployment of advanced healthcare technologies.
Flex Capital
A private equity and venture capital firm that provides growth capital and operational expertise to software and technology-enabled service companies.
Cigna Ventures
The corporate venture arm of Cigna, focusing on strategic investments in health services and digital health companies that improve the healthcare experience.
What's next for Datavant?
With the support of its latest capital injection, Datavant is well-positioned to scale its enterprise operations and expand its footprint within the global medical research community. The company's strategic roadmap likely involves deepening its integration capabilities with major health systems and life sciences organizations to further reduce friction in data exchange. As the industry moves toward more data-driven clinical trials and personalized medicine, Datavant's role in ensuring secure, high-fidelity data connectivity will be paramount. Future growth will likely focus on enhancing its compliance frameworks and expanding its network of data partners to maintain its competitive advantage in the rapidly evolving health-tech landscape.
See full Datavant company page
